Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 3/20 | 0.51 |
| ▸ | CCNC | P24863 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 5/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.43 |
| ▸ | CDK9 | P50750 | 10/20 | 0.43 |
| ▸ | CDK2 | P24941 | 3/20 | 0.42 |
| ▸ | CDK7 | P50613 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12056830 | 0.93 | CSF1R (0.50) | CSF1RCCNCCDK8FYNCCNT1 | |
| SCHEMBL12056880 | 0.93 | CSF1R (0.50) | CSF1RCCNCCDK8FYNCCNT1 | |
| SCHEMBL12064807 | 0.90 | CCNT1 (0.54) | CSF1RCCNCCDK8FYNCCNT1 | |
| SCHEMBL5203867 | 0.89 | CCNC (0.60) | CSF1RCCNCCDK8FYNCCNT1 | |
| SCHEMBL12698727 | 0.89 | CCNC (0.60) | CSF1RCCNCCDK8FYNCCNT1 | |
| SCHEMBL12064718 | 0.89 | CCNT1 (0.54) | CSF1RCCNCCDK8FYNCCNT1 | |
| SCHEMBL19447189 | 0.88 | CSF1R (0.57) | CSF1RCCNCCDK8FYNCCNT1 | |
| SCHEMBL12064822 | 0.87 | FYN (0.52) | CSF1RCCNCCDK8FYNCCNT1 | |
| SCHEMBL12064719 | 0.87 | CSF1R (0.59) | CSF1RCCNCCDK8FYNCCNT1 | |
| SCHEMBL12065006 | 0.86 | BRAF (0.50) | CSF1RCCNCCDK8FYNCCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084456-B2 | Pyrazine-based tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-12-27 | — | — | US | disclosed |
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | CYTOPIA PTY LTD (AU) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082894-A1 | Pyrazine-based tubulin inhibitors | TUBB1, TUBA1C, TUBB | CSF1R 2097/4885CCNC 540/4885CDK8 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.